Cheryl Gault, Director at Rapport Therapeutics, Inc. (RAPP), bought 3,600 shares at $27.35 ($98K) on 2026-10-23, disclosed to the SEC on 2026-10-23.
Open-market purchase of $98k RAPP by Director. Below the thresholds we flag for high-conviction alerts (no C-suite role, rare reversal, cluster, or A-grade history).
Nothing distinguishes this filing.
| Filing → |
| RAPP | BUY | 2026-10-22 | $974K | — | Filing → |
| RAPP | BUY | 2026-10-22 | $100K | — | Filing → |
| RAPP | BUY | 2026-10-22 | $249K | — | Filing → |